chondroitin and diacerein

Topics: Aged; Amino Acids, Sulfur; Anthraquinones; Boswellia; Chondroitin; Dietary Supplements; Gelatin; Glucosamine; Humans; Hydroxyproline; Osteoarthritis; Persea; Phytotherapy; Plant Oils; Protein Hydrolysates; S-Adenosylmethionine; Soybean Oil

Osteoarthritis (OA), by far the most common form of arthritis, has a growing impact on health care. Progress in understanding its pathophysiological processes has led to the identification of promising therapeutic targets, with disease-modifying osteoarthritis drugs (DMOADs) having the most potential. Numerous nonpharmaceutical measures and pharmacological interventions that slow the progression of the disease also have been developed. Several new classes of molecules that inhibit one or more OA pathophysiological processes have been discovered, and a number of these are under clinical evaluation to test their potential to alter the disease process in humans. Recent data from clinical trials have demonstrated that agents able to specifically block key disease mechanisms can effectively retard the progression of structural changes in knee OA patients. These studies are ushering the field into a new era in the development of DMOADs and, hence, the prospect of a cure for this disease.

Topics: Acetates; Anthraquinones; Antirheumatic Agents; Chondroitin; Clinical Trials as Topic; Diphosphonates; Disease Progression; Doxycycline; Glucosamine; Humans; Hyaluronic Acid; Matrix Metalloproteinase Inhibitors; Osteoarthritis; Pyrroles; Risk Factors

Osteoarthritis represents an advanced stage of disease progression caused in part by injury, loss of cartilage structure and function, and an imbalance in inflammatory and noninflammatory pathways. The burden of this disease will increase in direct proportion to the increase in the older adult population. Research on current and experimental treatment protocols are reviewed, including the effect of hyaluronic acid in both in vitro and in vivo studies, autologous chondrocyte and osteochondral plug implantation, and gene therapy. Disease-modifying osteoarthritis drugs and in vivo studies of glucosamine and chondroitin sulfate are reviewed.

Topics: Adjuvants, Immunologic; Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Camellia sinensis; Cartilage, Articular; Chondrocytes; Chondroitin; Forecasting; Genetic Therapy; Glucosamine; Humans; Hyaluronic Acid; Osteoarthritis; Phytotherapy; Plant Extracts

Glucosamine, chondroitin and diacerein are natural compounds commonly used in treating osteoarthritis. Their concomitant intake may trigger drug-natural product interactions. Cytochrome P450 (CYP) has been implicated in such interactions. Cytochrome P450 2D6 (CYP2D6) is a major hepatic CYP involved in metabolism of 25% of the clinical drugs. This study aimed to investigate the inhibitory effect of these antiarthritic compounds on CYP2D6.. CYP2D6 was heterologously expressed in. The high-performance liquid chromatography (HPLC)-based dextromethorphan. Glucosamine, chondroitin and diacerein unlikely cause clinical interaction with the drug substrates of CYP2D6. Rhein, exhibits only low potential to cause

Topics: Anthraquinones; Chondroitin; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Glucosamine; Humans; Microsomes, Liver; Molecular Docking Simulation

The aim of the present study was to compare the molecular and morphological effects of diacerein and glucosamine-chondroitin drug treatment and intra-articular injection therapy of human deciduous dental pulp stem cells (hDPSCs) in a rat knee model of induced osteoarthritis (OA).. Thirty-six adult male rats were randomly separated into six groups: Control group (without induction of OA), osteoarthritis group 60 (induction of OA, saline gavage started on day 14 and performed for 60 days, followed by euthanasia), osteoarthritis group (induction of OA and euthanasia after 14 days), diacerein group, glucosamine-chondroitin group, and mesenchymal stem cell group. The drug-treated groups were gavaged with 50 mg/kg of diacerein and 400/500 mg/kg of glucosamine-chondroitin starting on dat 14 for 60 days. The cell therapy-treated group received an intra-articular single dose of 8 × 105 hDPSCs on day 14, and euthanasia was performed after 60 days. Lateral femoral condyles were collected and prepared for immunohistochemistry and light microscopy procedures.. The morphological features and immunoexpression of SOX-5, IHH, MMP-8, MMP-13, and Type II collagen were statistically analysed. Our data suggest that hDPSC therapy contributes more actively and effectively in the structural reorganization of lateral femoral condyles. In contrast, the glucosamine-chondroitin sulphate treatment was more effective in inflammatory control, while diacerein showed better results associated with the maintenance of the primordial cartilage.. The positive therapeutic effect of daily administered conventional drugs can be confirmed in a rat model of OA. However, one single dose of locally administered hDPSCs provides significant improvement in tissue regeneration in an OA model.

Topics: Animals; Anthraquinones; Chondroitin; Dental Pulp; Disease Models, Animal; Dose-Response Relationship, Drug; Glucosamine; Humans; Injections, Intra-Articular; Male; Mesenchymal Stem Cells; Osteoarthritis; Rats; Rats, Wistar

Besides the management of symptoms of osteoarthritis, a lot of interest was raised for molecules aiming at slowing down the structural progression of the disease. This paper summarizes the currently available data allowing to discuss the efficacy and tolerance of these chemical entities.

Topics: Anthraquinones; Anti-Inflammatory Agents, Non-Steroidal; Chondroitin; Disease Progression; Glucosamine; Humans; Hyaluronic Acid; Osteoarthritis